Technology  May 3, 2016

Nivalis cites increased losses in first quarter

BOULDER — Clinical-stage pharmaceutical company Nivalis Therapeutics Inc. on Tuesday reported a first-quarter loss of $7.8 million, or 51 cents a share.

The Boulder-based company (Nasdaq: NVLS), which went public last June and remains pre-revenue, is developing drug candidates for the treatment of cystic fibrosis, including lead candidate N91115.

The loss for the quarter ending March 31 was a substantial increase from the net loss of $4.3 million in the first quarter of 2015, before the company went public. Nivalis said the loss primarily was the result of increased research and development expenses associated with the Phase 2 clinical program, as well as other related development costs for N91115. It also cited increased general and administrative costs related to becoming and operating as a publicly traded company.

SPONSORED CONTENT

Ways to thank a caregiver

If you have a caregiver or know someone who has been serving as a primary caregiver, March 3rd is the day to reach out and show them how much they are valued!

“We are making progress toward our goal of improving clinical outcomes for patients with cystic fibrosis with encouraging recruitment in our ongoing Phase 2 study” of the drug, said Jon Congleton, president and chief executive of Nivalis, in a statement that accompanied the earnings report.

Near the close of trading Tuesday, Heska shares were up 31 cents or 7.4 percent at $4.50.

Dallas Heltzell
With BizWest since 2012 and in Colorado since 1979, Dallas worked at the Longmont Times-Call, Colorado Springs Gazette, Denver Post and Public News Service. A Missouri native and Mizzou School of Journalism grad, Dallas started as a sports writer and outdoor columnist at the St. Charles (Mo.) Banner-News, then went to the St. Louis Post-Dispatch before fleeing the heat and humidity for the Rockies. He especially loves covering our mountain communities.
Sign up for BizWest Daily Alerts